Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Blood (2022) 140 (Supplement 1): 215–216.

https://doi.org/10.1182/blood-2022-164584

Published: 2022

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition

Blood (2018) 132 (Supplement 1): 107.

https://doi.org/10.1182/blood-2018-99-118747

Published: 2018

Journal Articles

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Clemence Marcault, MD, Geoffroy Venton, Lauris Gastaud, MD, Lionel Mannone, MD, Jerome Rey, MD, Evelyne D'Incan, MD, Colombe Saillard, MD, Aude Charbonnier, MD, Sophie Raynaud, MD PhD, Norbert Vey, Thomas Cluzeau, MDPhD

Blood (2017) 130 (Supplement 1): 2615.

https://doi.org/10.1182/blood.V130.Suppl_1.2615.2615

Published: 2017

Journal Articles

Clonal Selection in Therapy Related Myelodysplastic Syndromes Under Azacitidine Treatment

Anne Calleja, Chimene Moreilhon, PhD, Jean Michel Karsenti, MD, Lauris Gastaud, MD, Lionel Mannone, MD, Berengere Dadone, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Sophie Raynaud, MD PhD, Thomas Cluzeau, MDPhD

Blood (2017) 130 (Supplement 1): 5297.

https://doi.org/10.1182/blood.V130.Suppl_1.5297.5297

Published: 2017

Journal Articles

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Blood (2017) 130 (Supplement 1): 1722.

https://doi.org/10.1182/blood.V130.Suppl_1.1722.1722

Published: 2017

Journal Articles

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

Virginie Chesnais, Marie-Laure Arcangeli, Caroline Delette, Alice Rousseau, Hélène Guermouche, Carine Lefevre, Sabrina Bondu, M’boyba Diop, Meyling Cheok, Nicolas Chapuis, Laurence Legros, Sophie Raynaud, Lise Willems, Didier Bouscary, Evelyne Lauret, Olivier A. Bernard, Olivier Kosmider, Françoise Pflumio, Michaela Fontenay

Blood (2017) 129 (4): 484–496.

https://doi.org/10.1182/blood-2016-03-707745

Published: 2017

Includes: Supplemental data

Journal Articles

Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes

Virginie Chesnais, Marie-laure Arcangeli, PhD, Caroline Delette, Alice Rousseau, M'boyba Khadija Diop, Andrea Lefevre, Meyling H. Cheok, MSPharm, PhD, Nicolas Chapuis, PharmD, PhD, Laurence Legros, MD PhD, Sophie Raynaud, MD, Lise Willems, MD PhD, Didier Bouscary, MD PhD, Evelyne Lauret, PhD, Olivier A. Bernard, PhD, Olivier Kosmider, MD PhD, Francoise Pflumio, PhD, Michaela Fontenay, MD PhD

Blood (2016) 128 (22): 3153.

https://doi.org/10.1182/blood.V128.22.3153.3153

Published: 2016

Journal Articles

Targeted Sequencing for Clinical Investigation in Chronic Lymphocytic Leukemia

Damien Roos-Weil, Jérôme Lambert, MD PhD, Nathalie M. Droin, PhD, Frederik Damm, MD PhD, Romain Guieze, MD PhD, M'boypa Diop, Pierre Feugier, MD PhD, Stéphane Leprêtre, MD, Xavier Troussard, MD PhD, Vincent Ribrag, MD, Sandrine Vaudaux, Roselyne Delepine, Sophie Raynaud, MD, Julie Lejeune, Claude Lesty, Olivier A. Bernard, PhD, Florence Nguyen-Khac, MD PhD

Blood (2016) 128 (22): 3202.

https://doi.org/10.1182/blood.V128.22.3202.3202

Published: 2016

Journal Articles

Hemoglobin Level at Azacitidine Onset Is a Prognostic Factor of Unachievement of Three Azacitidine Cycles in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Anne Calleja, Jean Michel Karsenti, Lauris Gastaud, MD, Georges Garnier, Jean Gutnecht, Daniel Re, MD, Laurence Legros, MD PhD, Lionel Mannone, Patrick Auberger, PhD, Sophie Raynaud, MD, Thomas Cluzeau, MD PhD

Blood (2016) 128 (22): 5529.

https://doi.org/10.1182/blood.V128.22.5529.5529

Published: 2016

Journal Articles

Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Cecile Bally, Jacqueline Lehmann-Che, Bruno Cassinat, PharmD, PhD, Lionel Ades, MD PhD, Eric Letouze, Pierre Hirsch, Marie-Joelle Mozziconacci, Sophie Raynaud, MD, Eric Delabesse, PharmD, PhD, Madalina Uzunov, MD, Mathilde Hunault, MD PhD, Eric Lippert, PhD, Hélène Lapillonne, MD PhD, Christophe Ferrand, PhD, Carine Gervais, MD, Nathalie Gachard, PhD, Agnès Guerci, MD PhD, Pierre Fenaux, MD PhD, Hugues de The, MD PhD

Blood (2016) 128 (22): 2892.

https://doi.org/10.1182/blood.V128.22.2892.2892

Published: 2016

Journal Articles

Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)

Thomas Cluzeau, MD, PhD, Guillaume Robert, PhD, Jean Michel Karsenti, MD, Frederic Luciano, PhD, Nicolas Mounier, MD, PhD, Jill Patrice Cassuto, MD, PhD, Lionel Ades, Sophie Raynaud, MD, PhD, Pierre Fenaux, MD, PhD, Patrick Auberger, PhD

Blood (2013) 122 (21): 1568.

https://doi.org/10.1182/blood.V122.21.1568.1568

Published: 2013

Journal Articles

Mutational and Cytogenetic Analyses Of 177 CLL Patients With Trisomy 12: A Retrospective Study Of The CLL French Intergroup

Damien Roos-Weil, MD, Florence Nguyen-Khac, MD, PhD, Sylvie Chevret, Clémence Roux, Cyrille Touzeau, Adrien Cosson, Florence Cymbalista, MD, PhD, Pierre Feugier, MD, PhD, Stéphane Leprêtre, MD, Marie-Christine Bene, MD, Sophie Raynaud, MD, PhD, Laurent Sutton, MD, Frederic Davi, MD, PhD, Veronique Leblond, MD

Blood (2013) 122 (21): 4144.

https://doi.org/10.1182/blood.V122.21.4144.4144

Published: 2013

Journal Articles

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Mathilde Lamarque, Sophie Raynaud, Raphael Itzykson, Sylvain Thepot, Bruno Quesnel, Francois Dreyfus, Odile Beyne Rauzy, Pascal Turlure, Norbert Vey, Christian Recher, Caroline Dartigeas, Laurence Legros, Jacques Delaunay, Sorin Visanica, Aspasia Stamatoullas, Pierre Fenaux, Lionel Adès

Blood (2012) 120 (25): 5084–5085.

https://doi.org/10.1182/blood-2012-09-453555

Published: 2012

Journal Articles

Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

Thomas Cluzeau, MD, PhD, Nicolas Mounier, MD, PhD, Valentine Richez, Jean-Michel Karsenti, MD, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Henri Vinti, MD, Laurence Legros, MD, PhD, Lauris Gastaud, Antoine Thyss, MD, Georges Garnier, MD, Daniel Re, MD, Nathalie Montagne, MD, Jean Gutnecht, MD, Patrick Auberger, MD, PhD, Sophie Raynaud, Jill-Patrice Cassuto, MD

Blood (2012) 120 (21): 2813.

https://doi.org/10.1182/blood.V120.21.2813.2813

Published: 2012

Journal Articles

Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.

Cecile Bally, Lionel Ades, MD, PhD, Aline Renneville, MD, Sophie Raynaud, Virginie Eclache, MD, Thomas Cluzeau, MD, PhD, Mathilde Hunault-Berger, MD, PhD, Aspasia Stamatoullas, MD, Christian Bastard, MD, Michaela Fontenay, MD, PhD, Marie-Joelle Mozziconacci, MD, PhD, Claude Preudhomme, Hugues de The, MD, PhD, Pierre Fenaux, MD, PhD, Jacqueline Lehmann-Che, PharmD, PhD

Blood (2012) 120 (21): 2809.

https://doi.org/10.1182/blood.V120.21.2809.2809

Published: 2012

Journal Articles

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Lionel Ades, MD, PhD, Mathilde Lamarque, MD, Sophie Raynaud, Raphael Itzykson, Sylvain Thepot, Bruno Quesnel, MD, PhD, Francois Dreyfus, Odile Beyne Rauzy, MD, PhD, Pascal Turlure, MD, Norbert Vey, MD, Christian Recher, MD, Caroline Dartigeas, MD, Laurence Legros, MD, PhD, Jacques Delaunay, MD, Sorin Visanica, Aspasia Stamatoullas, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 422.

https://doi.org/10.1182/blood.V120.21.422.422

Published: 2012

Journal Articles

Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients

Thomas Cluzeau, MD, PhD, Chimène Moreilhon, Nicolas Mounier, MD, PhD, Jean-Michel Karsenti, MD, Lionel Mannone, MD, Faezeh Legrand, MD, PhD, Valentine Richez, Lauris Gastaud, Antoine Thyss, MD, Georges Garnier, MD, Daniel Re, MD, Nathalie Montagne, MD, Jean Gutnecht, MD, Patrick Auberger, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud

Blood (2012) 120 (21): 4936.

https://doi.org/10.1182/blood.V120.21.4936.4936

Published: 2012

Journal Articles

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Thomas Cluzeau, MD, PhD, Guillaume Robert, Jean-Michel Karsenti, MD, Frederic Luciano, Alexandre Puissant, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Aline Renneville, MD, Claude Preudhomme, Pierre Fenaux, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud, Nicolas Mounier, MD, PhD, Patrick Auberger, MD, PhD

Blood (2012) 120 (21): 701.

https://doi.org/10.1182/blood.V120.21.701.701

Published: 2012

Journal Articles

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Mathilde Lamarque, MD, Sophie Raynaud, Raphael Itzykson, MD, Sylvain Thepot, Bruno Quesnel, Francois Dreyfus, Odile Beyne Rauzy, Pascal Turlure, Norbert Vey, MD, Christian Recher, MD, PhD, Caroline Dartigeas, MD, Laurence Legros, Jacques Delaunay, Sorin Visanica, Aspasia Stamatoullas, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2011) 118 (21): 972.

https://doi.org/10.1182/blood.V118.21.972.972

Published: 2011

NARROW

DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Clonal Selection in Therapy Related Myelodysplastic Syndromes Under Azacitidine Treatment

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes

Targeted Sequencing for Clinical Investigation in Chronic Lymphocytic Leukemia

Hemoglobin Level at Azacitidine Onset Is a Prognostic Factor of Unachievement of Three Azacitidine Cycles in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)

Mutational and Cytogenetic Analyses Of 177 CLL Patients With Trisomy 12: A Retrospective Study Of The CLL French Intergroup

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only